Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

NCT02979613 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

490

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: TAF
DRUG: TDF
DRUG: TAF Placebo
DRUG: TDF Placebo

Sponsor

Gilead Sciences